Method for the treatment or prevention of lower urinary tract symptoms

Abstract

This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

1 . Method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.  
     
     
         2 . The method according to  claim 1  wherein the lower urinary tract symptoms are bladder/urethra dyssynergia, bladder neck dyssynergia or Hinman syndrome in male individuals.  
     
     
         3 . The method according to  claim 1  wherein the lower urinary tract symptoms are micturition urgency in female individuals.  
     
     
         4 . The method according to  claim 1  wherein the lower urinary tract symptoms are abacterial prostatitis, stress prostatitis, trigonitis or orchialgia in male individuals.  
     
     
         5 . The method according to  claim 1  wherein the lower urinary tract symptoms are bladder instability or interstitial cystitis in male or female individuals.  
     
     
         6 . The method according to  claim 1  wherein the pelvic pain is related to abacterial prostatitis, stress prostatitis, prostatodynia, urethral syndromes, trigonitis, or orchialgia in male individuals.  
     
     
         7 . The method according to  claim 1  wherein the pelvic pain is interstitial cystitis in male or female individuals.  
     
     
         8 . The method according to  claim 1  wherein the selective estrogen receptor modulator is a triphenylalkene compound, a triphenylalkane compound, a benzothiophene compound, EM652, EM800, EM776, EM651, EM312, ICI 182780, ERA-923, zindoxifene, deacetylated zindoxifene, ZK119010, TSE-4247, lasoxifene, a lasoxifene analogue, nafoxidine, basedoxifene, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 or EM 319.  
     
     
         9 . The method according to  claim 1  wherein the selective estrogen receptor modulator is a compound with low or no estrogenic activity.  
     
     
         10 . The method according to  claim 9  wherein the selective estrogen receptor modulator is selected from a group consisting of: 
 (Z)-2-[3-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol,  
 (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy} ethanol (fispemifene),  
 (Z)-{2-[3-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethyl}dimethylamine,  
 (E)-3-{4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol,  
 (E)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol,  
 (Z)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, or raloxifene,  
 or any isomer, isomer mixture or pharmaceutically acceptable salt thereof.  
 
     
     
         11 . The method according to  claim 9  wherein the selective estrogen receptor modulator is fispemifene.